|
KMID : 0371319930440030322
|
|
Journal of the Korean Surgical Society
1993 Volume.44 No. 3 p.322 ~ p.333
|
|
|
The Effectiveness of the Antiidiotypic Monoclonal Antibody Therapy Conjugasted to KLH and BCG in Malignant Melanoma
|
|
Bae Sung-Han
|
|
|
Abstract
|
|
|
The human HMW-MAA meets the criteria to be used as a target for active and passive immunotherapy. We have utilized murine antiidiotypic monoclonal monoclonal antibodies to immplement active specific immunotherapy in patients with melanoma. The
characterizations of a large panel of murine antiidiotypic monoclonal antibodies elicited with syngeneic monoclonal antibodies to distinct determints of HMM-MAA has shown that the antiidiotypic monoclonal antibody bears the mirror image of
HMW-WAA,
since it induces humoral and cellular immunity to HMW-MAA in hosts. The antiidiotypic monoclonal antibody has been utilized in a phase 1 cinical trial in patients with stage IV melanoma. Fifteen patients have been immunized with 2 mg 2 ml of
MoAb₂conjugated to KLH and mixed with BCG and 12 patients with 2 mg/2ml of MoAb₂alone. Imunizations have been administered on day 0.7, and 28 subcutaeously.
Antibodies reacting with melanoma cells have been detected in 73% of patients immunized with MoAb₂conjugated to KLH and mixed with BCG and in only 16% of the patients immunized with the unconjugated MoAb₂. About 86% of the patients immunized
with
MoAb₂conjugated to KLH and mixed with BCG and about 58% of those immunized with MoAb₂devloped No marked difference was found in the development of antimouse Ig antibodies between the two groups of patients.
The repeated injections of murine antiidiotypic monoclonal antibodies were not associated with any side effects.
There results indicate that the conjugation ot a carrier and mixing with an adjuvant can markedly enhance the ability of murine antiidiotypic MoAb₂to elicit immunity to melanoma cell in patients with melanoma
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|